Alcon has completed its purchase of Aerie Pharmaceuticals, enhancing its ophthalmic pharmaceutical portfolio.
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.
Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.
Alcon CEO David Endicott says Alcon has a “rich history in the ophthalmic pharmaceutical space… we are excited to add Aerie’s significant technical expertise to Alcon R&D, which enhances our efforts to build a compelling portfolio of ophthalmic pharmaceuticals”.
Alcon intends to fully integrate Aerie into its business. The company previously disclosed it used debt to fund the transaction for a total purchase consideration of approximately US$930 million.